NEUROONE MEDICAL TECHNOLOGIES Corp NMTC
Last close
0.92
2026-10-23
Market cap
$8.4M
2026-06-30 share count
52-week range
0.88 - 6.12
Valuation FY2025 figures against the last close
P/S0.9x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.09
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.1M | $3.5M | $2.0M | $171.2K | $178.1K | — | — | — | — | $0 |
| Cost of revenue | $4.0M | $2.4M | $1.5M | $242.0K | $275.9K | — | — | — | — | — |
| Gross profit | $5.1M | $1.1M | $456.5K | -$70.8K | -$97.7K | — | — | — | — | — |
| R&D | $5.0M | $5.1M | $6.9M | $4.9M | $3.9M | $2.1M | $1.5M | — | $735.3K | — |
| SG&A | $7.4M | $7.9M | $6.9M | $7.0M | $6.3M | $4.8M | $4.3M | — | $2.3M | $32.6K |
| Total operating expenses | $12.4M | $13.0M | $13.9M | $11.9M | $10.2M | $6.8M | $5.8M | — | $3.1M | $32.6K |
| Operating income | -$4.2M | -$11.9M | -$12.0M | -$10.0M | -$10.2M | -$4.9M | -$5.8M | — | -$3.1M | -$32.6K |
| Interest expense | — | — | — | — | $3.1K | $7.5M | $284.6K | — | $1.4M | — |
| Pre-tax income | -$3.6M | -$12.3M | -$11.9M | -$10.0M | -$9.7M | -$2.0M | — | — | — | -$32.6K |
| Income tax | — | — | — | — | $271.1K | — | — | — | — | $0 |
| Net income | -$3.6M | -$12.3M | -$11.9M | -$10.0M | -$9.9M | -$13.6M | -$6.8M | — | -$5.1M | -$47.8K |
| EPS, basic | -0.09 | -0.46 | -0.65 | -0.63 | -0.93 | — | — | — | — | — |
| EPS, diluted | -0.09 | -0.46 | -0.65 | -0.63 | -0.93 | -2.52 | -0.57 | — | -0.77 | -0.01 |
| Shares, diluted (wtd. avg.) | 40.2M | 26.8M | 18.1M | 16.0M | 10.7M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.6M | $1.5M | $5.3M | $8.2M | $6.9M | $4.0M | $260.7K | $13.3K | $26.5K | $522.2K |
| Short-term investments | — | — | — | $3.0M | — | — | — | — | — | — |
| Receivables | $1.3M | $176.6K | — | $33.2K | $48.3K | — | — | — | — | — |
| Inventory | $2.2M | $2.6M | $1.7M | $704.5K | $98.3K | — | — | — | — | — |
| Total current assets | $10.2M | $4.6M | $7.3M | $12.2M | $7.3M | $4.2M | $301.8K | $18.6K | $33.6K | $576.0K |
| Property, plant and equipment | $259.2K | $416.8K | $525.8K | $353.6K | $223.3K | $166.0K | $52.0K | — | — | — |
| Other intangibles | $44.9K | $67.3K | $89.6K | $111.9K | $134.2K | $156.5K | $178.8K | $200.1K | $216.4K | $180.9K |
| Total assets | $10.8M | $5.4M | $8.1M | $12.8M | $7.9M | $4.8M | $532.6K | $218.7K | $250.0K | $756.9K |
| Accounts payable | $1.0M | $1.0M | $685.1K | $927.7K | $528.8K | $762.5K | $1.2M | $221.2K | — | $22.4K |
| Short-term debt | — | — | — | — | — | $1.0M | — | $283.0K | $253.0K | $50.0K |
| Total current liabilities | $2.3M | $2.2M | $1.8M | $3.1M | $1.2M | $2.4M | $1.8M | $3.8M | $3.9M | $677.2K |
| Total liabilities | $3.7M | $4.5M | $1.8M | $3.2M | $1.4M | $2.7M | $1.8M | $4.6M | $5.3M | $1.0M |
| Retained earnings | -$78.6M | -$75.0M | -$62.7M | -$50.8M | -$40.8M | -$30.9M | -$17.2M | -$10.5M | -$5.3M | -$266.4K |
| Total equity | $7.1M | $822.0K | $6.2M | $9.6M | $6.6M | $2.1M | -$1.2M | -$4.4M | -$5.0M | -$266.2K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.8M | -$11.0M | -$12.9M | -$7.5M | -$8.6M | -$3.4M | -$5.4M | — | -$2.1M | -$21.1K |
| Depreciation and amortisation | $239.4K | $224.5K | $177.0K | $118.6K | $80.7K | $47.6K | $27.6K | — | — | — |
| Stock-based compensation | $1.3M | $1.3M | $1.1M | $947.2K | — | — | $324.2K | — | $76.8K | — |
| Capital expenditure | $81.7K | $120.2K | $384.1K | $275.2K | $67.1K | $122.4K | $58.4K | — | — | — |
| Investing cash flow | -$81.7K | -$120.2K | $2.6M | -$3.2M | -$67.1K | -$122.4K | -$123.4K | — | -$91.7K | $0 |
| Financing cash flow | $8.0M | $7.3M | $7.4M | $12.0M | $11.5M | $7.3M | $5.8M | — | $1.7M | $21.1K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-007245.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | — | — | — | $178.1K | $171.2K | $2.0M | $3.5M | $9.1M |
| Gross profit | — | — | — | — | — | -$97.7K | -$70.8K | $456.5K | $1.1M | $5.1M |
| Net income | -$47.8K | -$5.1M | — | -$6.8M | -$13.6M | -$9.9M | -$10.0M | -$11.9M | -$12.3M | -$3.6M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event Item 8.01
- Accounts can no longer be relied on The company is telling investors that figures it has already published are wrong. Rare, and about as direct as a filing gets. Item 4.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |